Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16245212 | 0.83 | LMNA (0.51) | LMNASMN1; SMN2GLARAB9AKDM4E | |
| SCHEMBL14930267 | 0.83 | GLA (0.50) | LMNASMN1; SMN2GLAKDM4EKMT2A | |
| SCHEMBL14930241 | 0.81 | MAPT (0.50) | KDM4EKMT2AHTTPKM | |
| SCHEMBL3019244 | 0.76 | ALPL (0.57) | LMNAALPL | |
| SCHEMBL16244790 | 0.75 | LMNA (0.42) | LMNASMN1; SMN2GLARAB9AKDM4E | |
| SCHEMBL16012966 | 0.74 | SMN1; SMN2 (0.66) | SMN1; SMN2GLAKDM4EKMT2AGAA | |
| SCHEMBL5173975 | 0.73 | KDM4E (0.45) | SMN1; SMN2RAB9AKDM4EALDH1A1KMT2A | |
| SCHEMBL1516692 | 0.72 | FBP1 (0.44) | LMNASMN1; SMN2RAB9AKDM4EALDH1A1 | |
| SCHEMBL31053304 | 0.72 | FBP1 (0.44) | LMNASMN1; SMN2RAB9AKDM4EALDH1A1 | |
| SCHEMBL30714339 | 0.71 | CA1 (0.55) | LMNASMN1; SMN2RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MC2R, NR3C2, REN | LMNA 2633/4885SMN1; SMN2 4689/4885GLA 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.